Eight-Year Experience With Botulinum Toxin Type-A Injections for the Treatment of Nonneurogenic Overactive Bladder: Are Repeated Injections Worthwhile?
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: To investigate the efficacy and safety of repeated botulinum toxin type-A (BTX-A) injections for patients with drugrefractory nonneurogenic overactive bladder (NNOAB) and explore factors predictive of outcome. Methods: Data were collected from all patients receiving repeated BTX-A injections for drug-refractory NNOAB between 2004 and 2012. Trigone-sparing injections were administered under sedation with antibiotic prophylaxis. Patient characteristics including age, sex, preoperative urodynamics, injection number, BTX-A dose, complications, and patient global impression of improvement (PGI-I) scores were collected. Correlations between patient factors and outcomes were assessed by using Pearson’s chi-square tests. Results: Fifty-two patients with a mean age of 67.4 years (range, 26–93 years) received 140 BTX-A injections in total; 33 (64%), 15 (29%), and 4 patients (7%) received 2, 3 to 4, and 5 to 8 injections, respectively. Mean follow-up time was 49 months (range, 9–101 months). Nine patients developed urinary tract infection; additionally, 3 patients experienced transient urinary retention. Median PGI-I score was 2 out of 7 (interquartile range [IQR], 2). For 46 patients, the PGI-I score remained stable with the administration of each injection. Pearson chi-square tests revealed that male patients or reduced bladder compliance was associated with a higher (worse) PGI-I score. Median PGI-I scores for men and women were 3 (IQR, 1) and 2 (IQR, 1), respectively; additionally, median PGI-I scores for those with normal bladder compliance and those with reduced bladder compliance were 2 (IQR, 2) and 4.5 (IQR, 1), respectively. Median PGI-I scores and complication rates were the same in the older patient (≥70 years) and younger (<70 years) patient cohorts. Conclusions: Efficacy is maintained with repeated BTX-A injections. Patients including the elderly show a good degree of tolerability with a low complication rate. Male patients or reduced bladder compliance is associated with poorer outcomes.
Abstract
Purpose: To investigate the efficacy and safety of repeated botulinum toxin type-A (BTX-A) injections for patients with drugrefractory nonneurogenic overactive bladder (NNOAB) and explore factors predictive of outcome. Methods: Data were collected from all patients receiving repeated BTX-A injections for drug-refractory NNOAB between 2004 and 2012. Trigone-sparing injections were administered under sedation with antibiotic prophylaxis. Patient characteristics including age, sex, preoperative urodynamics, injection number, BTX-A dose, complications, and patient global impression of improvement (PGI-I) scores were collected. Correlations between patient factors and outcomes were assessed by using Pearson’s chi-square tests. Results: Fifty-two patients with a mean age of 67.4 years (range, 26–93 years) received 140 BTX-A injections in total; 33 (64%), 15 (29%), and 4 patients (7%) received 2, 3 to 4, and 5 to 8 injections, respectively. Mean follow-up time was 49 months (range, 9–101 months). Nine patients developed urinary tract infection; additionally, 3 patients experienced transient urinary retention. Median PGI-I score was 2 out of 7 (interquartile range [IQR], 2). For 46 patients, the PGI-I score remained stable with the administration of each injection. Pearson chi-square tests revealed that male patients or reduced bladder compliance was associated with a higher (worse) PGI-I score. Median PGI-I scores for men and women were 3 (IQR, 1) and 2 (IQR, 1), respectively; additionally, median PGI-I scores for those with normal bladder compliance and those with reduced bladder compliance were 2 (IQR, 2) and 4.5 (IQR, 1), respectively. Median PGI-I scores and complication rates were the same in the older patient (≥70 years) and younger (<70 years) patient cohorts. Conclusions: Efficacy is maintained with repeated BTX-A injections. Patients including the elderly show a good degree of tolerability with a low complication rate. Male patients or reduced bladder compliance is associated with poorer outcomes.
참고문헌 (26)
- Abrams P, "The standardisation of terminology of lower urinary tract function:report from the Standardisation Sub-committee of the International Continence Society", Neurourol Urodyn, 21, pp.167~178 (2002)
- Chapple CR, "The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis", Eur Urol, 54, pp.543~562 (2008)
- Brostrom S, "Persistence of antimuscarinic drug use", Eur J Clin Pharmacol, 65, pp.309~314 (2009)
- Gormley EA, "Diagnosis and treatment of overactive bladder (non-neurogenic)in adults: AUA", SUFU guideline, 2012, pp.188(6 Suppl), 2455~2463
- Allahdin S, "An overview of treatment of overactive bladder syndrome in women", J Obstet Gynaecol, 32, pp.217~221 (2012)
- Balchandra P, "Women’s perspective: intra-detrusor botox versus sacral neuromodulation for overactive bladder symptoms after unsuccessful anticholinergic treatment", Int Urogynecol J, 25, pp.1059~1064 (2014)
- Sahai A, "Improvement in quality of life after botulinum toxin-A injections for idiopathic detrusor overactivity: results from a randomized double-blind placebo-controlled trial", BJU Int, 103, pp.1509~1515 (2009)
- Rovner E, "Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder", Neurourol Urodyn, 30, pp.556~562 (2011)
- Tincello DG, "Botulinum toxin a versus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240 women (the RELAX study)", Eur Urol, 62, pp.507~514 (2012)
- Denys P, "Efficacy and safety of low doses of onabotulinumtoxinA for the treatment of refractory idiopathic overactive bladder: a multicentre, double-blind, randomised, placebo-controlled doseranging study", Eur Urol, 61, pp.520~529 (2012)
- Sahai A, "Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial", J Urol, 177, pp.2231~2236 (2007)
- Reitz A, "Do repeat intradetrusor botulinum toxin type a injections yield valuable results? Clinical and urodynamic results after five injections in patients with neurogenic detrusor overactivity", Eur Urol, 52, pp.1729~1735 (2007)
- Sahai A, "Repeated injections of botulinum toxin-A for idiopathic detrusor overactivity", Urology, 75, pp.552~558 (2010)
- Abeywickrama L, "Repeated botulinum toxin type A (Dysport) injections for women with intractable detrusor overactivity: a prospective outcome study", Int Urogynecol J, 25, pp.601~605 (2014)
- Dowson C, "Repeated botulinum toxin type A injections for refractory overactive bladder:medium-term outcomes, safety profile, and discontinuation rates", Eur Urol, 61, pp.834~839 (2012)
- Veeratterapillay R, "Discontinuation rates and inter-injection interval for repeated intravesical botulinum toxin type A injections for detrusor overactivity", Int J Urol, 21, pp.175~178 (2014)
- The American College of Obstetricians and Gynecologists, "OnabotulinumtoxinA and the bladder. Committee Opinion No. 604", Obstet Gynecol, 123, pp.1408~1411 (2014)
- Apostolidis A, "Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions:a European consensus report", Eur Urol, 55, pp.100~119 (2009)
- White WM, "Short-term efficacy of botulinum toxin a for refractory overactive bladder in the elderly population", J Urol, 180, pp.2522~2526 (2008)
- Brierly RD, "A prospective evaluation of detrusor ultrastructural changes in bladder outlet obstruction", BJU Int, 91, pp.360~364 (2003)
- Mirone V, "The detrusor muscle: an innocent victim of bladder outlet obstruction", Eur Urol, 51, pp.57~66 (2007)
- Gosling JA, "Modification of bladder structure in response to outflow obstruction and ageing", Eur Urol, 32(Suppl 1), pp.9~14 (1997)
- Liao LM, "Cross-sectional and longitudinal studies on interaction between bladder compliance and outflow obstruction in men with benign prostatic hyperplasia", Asian J Androl, 9, pp.51~56 (2007)
- Madersbacher S, "Interrelationships of bladder compliance with age, detrusor instability, and obstruction in elderly men with lower urinary tract symptoms", Neurourol Urodyn, 18, pp.3~15 (1999)
- Habashy D, "Botulinum toxin (OnabotulinumtoxinA) in the male non-neurogenic overactive bladder: clinical and quality of life outcomes", BJU Int, 116(Suppl 3), pp.61~65 (2015)
- Mohee A, "Eardley I. Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB)", BJU Int, 111, pp.106~113 (2013)